Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 ...

MOUNTAIN VIEW, Calif., Dec. 12, 2024 /PRNewswire/ -- Corvus Robotics, a provider of autonomous inventory management systems, today announced that it has recruited Rob Stevens, former VP of ...